



MedGenome secures \$30 mn funding led by Sequoia India, Sofina

Press Trust of India | New Delhi
August 29, 2017 Last Updated at 12:48 IST

ALSO READ

[Visa woes: Cognizant to ramp up hiring in US](#)

[Cognizant Q1 Net up 26%, steps up hiring in US](#)

[Cognizant incurs \\$27 mn in cost on India corruption probe](#)

[Employee separation offer 1st time in India, US: Cognizant](#)

[IT sector 'robust', layoffs part of appraisal process: Govt](#)

Genomics research and diagnostics company MedGenome has secured USD 30 million (around Rs 192 crore) in series C funding led by Sequoia [India](#) and Sofina sa and aims to accelerate adoption of cost-effective genetic diagnostics.

The latest funding round also saw participation by Zodius Capital; Kris Gopalakrishnan, co-founder and former CEO of [Infosys](#) and Lakshmi Narayanan, former CEO of Cognizant, a company release said.

The funding will accelerate development of the company's diagnostics tests and expand market penetration by increasing customer awareness on the

importance of genetic tests.

Additionally, the funding will be used to broaden biomarker discovery programs, it said.

"MedGenome has established leadership in genetic diagnostics for inherited diseases in [India](#). We will now expand DNA-based testing to cover infectious diseases like tuberculosis," said Sam Santhosh, founder and Chairman of MedGenome.

MedGenome's diagnostics tests include first liquid biopsy 'OncoTrack' for monitoring cancer treatment, non-invasive prenatal screening test (NIPT) for pregnant women, carrier screening test for couples planning on a baby, and whole exome sequencing test for identifying mutations in rare diseases.

"We believe MedGenome's efforts will have a definitive impact on healthcare delivery in [India](#) and around the world," said Xiao-Tian Loi, Investment Manager at Sofina.

Gopalakrishnan said: "I am investing in MedGenome which addresses the extraordinary opportunities that exist today in the development of precision medicine".

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)